Poltreg S.A.

Warsaw Stock Exchange PTG.WA

Poltreg S.A. EPS (Diluted) for the year ending December 31, 2023: USD -0.74

Poltreg S.A. EPS (Diluted) is USD -0.74 for the year ending December 31, 2023, a -1,254.72% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Poltreg S.A. EPS (Diluted) for the year ending December 31, 2022 was USD 0.06, a 123.27% change year over year.
Poltreg S.A. EPS (Diluted) for the year ending December 31, 2021 was USD -0.27, a -253.67% change year over year.
Poltreg S.A. EPS (Diluted) for the year ending December 31, 2020 was USD -0.08, a 15.70% change year over year.
Poltreg S.A. EPS (Diluted) for the year ending December 31, 2019 was USD -0.09, a 15.85% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

Warsaw Stock Exchange: PTG.WA

Poltreg S.A.

CEO	Mr. Piotr Trzonkowsk
IPO Date	Nov. 23, 2021
Location	Poland
Headquarters	Waly Piastowskie 1 lok. 1508
Employees	25
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.

Key trends

Past 5 years